Edivoxetine (INN; code name LY-2216684) is a drug which acts as a selective norepinephrine reuptake inhibitor and was under development by Eli Lilly for attention-deficit disorder (ADD) and as an antidepressant treatment.[1][2] It was in phase III clinical trials, in 2012, for major depressive disorder, but failed to get approval.[1][3]

Clinical data
ATC code
  • None
Legal status
Legal status
  • Development terminated
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass339.402 g/mol g·mol−1
3D model (JSmol)


In a study published in 2010, edivoxetine succeeded to prove superiority over placebo, as measured by Hamilton Depression Rating Scale. However, effectiveness could be observed using the Self-Rated Quick Inventory of Depressive Symptomatology.[4]

In a study published in 2011, using the Montgomery–Åsberg Depression Rating Scale and the Sheehan Disability Scale, edivoxetine showed superiority over placebo, with higher response and remission rates.[5]

In December 2013, Eli Lilly announced that the clinical development of edivoxetine will be stopped due to lack of efficacy compared to SSRI alone in three separate clinical trials.[6]

Side effects

Side effects significantly associated with edivoxetine are headache, nausea, constipation, dry mouth and insomnia.[4]

The above-mentioned studies report increases of the cardiac rhythm, and one also increases of diastolic and systolic blood pressures.[4][5]

See also


  1. Jun Yan (March 2012). "Pipeline for new antidepressants flowing slowly". Psychiatric News. American Psychiatric Association. 47 (5): 1b–29. doi:10.1176/pn.47.5.psychnews_47_5_1-b. Retrieved 2012-04-27.
  2. "Statement on a nonproprietary name adopted by the USAN council - Edivoxetine" (PDF) (Press release). American Medical Association. 2012. Retrieved 2012-04-12.
  3. Chancellor D (November 2011). "The depression market". Nature Reviews. Drug Discovery. 10 (11): 809–10. doi:10.1038/nrd3585. PMID 22037032.
  4. Dubé S, Dellva MA, Jones M, Kielbasa W, Padich R, Saha A, Rao P (April 2010). "A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression". Journal of Psychiatric Research. 44 (6): 356–363. doi:10.1016/j.jpsychires.2009.09.013. PMID 19909980.
  5. Pangallo P, Dellva MA, D'Souza DN, Essink B, Russell J, Goldberger C (June 2011). "A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder". Journal of Psychiatric Research. 45 (6): 748–755. doi:10.1016/j.jpsychires.2011.03.014. PMID 21511276.
  6. https://investor.lilly.com/releasedetail.cfm?ReleaseID=811751
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.